Mekinist (trametinib tablets and oral solution – Novartis) — Cigna

Initial criteria

• Patient meets ONE of the following (i or ii): i. Patient has BRAF V600 mutation-positive disease; OR ii. Patient has BRAF fusion-positive disease; AND
• Patient meets ONE of the following (i or ii): i. The medication will be taken in combination with Tafinlar (dabrafenib capsules or tablets for oral suspension); OR ii. Patient has circumscribed glioma.

Approval duration

1 year